← Back to Clinical Trials
Recruiting NCT06241274

NCT06241274 Moxibustion in the Treatment of Hemorrhagic Cystitis After Allo-HSCT

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06241274
Status Recruiting
Phase
Sponsor Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Condition Moxibustion
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2024-08-15
Primary Completion 2025-09-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 55 Years
Study Type INTERVENTIONAL
Interventions
MoxibustionSymptomatic supportive treatment

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2024-08-15 with a primary completion date of 2025-09-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study was a prospective, multicenter, single-arm clinical study planned to enroll 60 patients who developed hemorrhagic cystitis after sexually allogeneic hematopoietic stem cell transplantation Patients with hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation were given symptomatic supportive treatment combined with moxibustion covering Shenque, Zhongguo, Guanyuan, and Qihai for 30 minutes every day for 14 days and urine routine was collected every day for 14 days to assess the severity of hemorrhagic cystitis and pain scores to evaluate the effectiveness of moxibustion in treating hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation.

Eligibility Criteria

Inclusion Criteria: 1. patients were fully aware of the study, participated voluntarily, and signed the informed consent form; 2. Age: 18-55 years old; 3. patients with hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation; Exclusion Criteria: 1. refusal to participate in this clinical study; 2. broken or sensitized skin corresponding to the moxibustion site; 3. allogeneic hematopoietic stem cell transplantationpatients pretreated with the Reduced-intensity conditioning.

Contact & Investigator

Central Contact

Yi Zhang

✉ zy188603@163.com

📞 +86 15639790587

Frequently Asked Questions

Who can join the NCT06241274 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 55 Years, studying Moxibustion. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06241274 currently recruiting?

Yes, NCT06241274 is actively recruiting participants. Contact the research team at zy188603@163.com for enrollment information.

Where is the NCT06241274 trial being conducted?

This trial is being conducted at Wuhan, China.

Who is sponsoring the NCT06241274 clinical trial?

NCT06241274 is sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. The trial plans to enroll 60 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology